脂必泰联合阿托伐他汀治疗冠心病合并高脂血症的效果  

Effect of Lipidetine combined with Atorvastatin in the treatment of coronary heart disease with hyperlipidemia

作　　者：张成龙 ZHANG Cheng-long(Department of Cardiology,People′s Hospital of Yunyang District in Shiyan City,Hubei Province,Shiyan 442500,China)

机构地区：[1]湖北省十堰市郧阳区人民医院心内科,湖北十堰442500

出　　处：《中国当代医药》2021年第1期78-80,共3页China Modern Medicine

摘　　要：目的探讨脂必泰联合阿托伐他汀治疗冠心病合并高脂血症患者的效果。方法选取2018年7月~2019年7月十堰市郧阳区人民医院收治的103例冠心病合并高脂血症患者,采用随机数字表法将其分为阿托伐他汀组(n=51)和联合治疗组(n=52)。阿托伐他汀组在基础治疗加以阿托伐他汀口服治疗,联合治疗组则采用脂必泰联合阿托伐他汀治疗。比较两组患者的总胆固醇(TC)、三酰甘油(TG)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)等血脂指标的控制情况,测定比较两组患者治疗前后的超敏C反应蛋白(hs-CRP)水平,并观察患者用药期间的不良反应发生情况。结果联合治疗组的TC、TG、LDL-C控制达标率均高于阿托伐他汀组(P<0.05)。两组的HDL-C控制达标率比较,差异无统计学意义(P>0.05)。治疗后,两组患者的hs-CRP均低于治疗前,且联合治疗组的hs-CRP低于阿托伐他汀组(P<0.05)。联合治疗组的不良反应总发生率为5.77%,低于阿托伐他汀组的19.61%,差异有统计学意义(P<0.05)。结论冠心病合并高脂血症患者应用脂必泰联合阿托伐他汀治疗,能发挥更佳的降脂效果,改善其血脂指标,并降低hs-CRP水平。Objective To investigate the effect of Lipopitride combined with Atorvastatin in the treatment of patients with coronary heart disease with hyperlipidemia.Methods A total of 103 patients with coronary heart disease and hyperlipidemia admitted to People′s Hospital of Yunyang District in Shiyan City from July 2018 to July 2019 were selected,and they were divided into Atorvastatin group(n=51)and combined treatment group(n=52)by random digital table method.Atorvastatin group was treated with Atorvastatin orally in the basic treatment,the combined treatment group was treated with Lipopitride combined with Atorvastatin.The control conditions of total cholesterol(TC),triacylglycerol(TG),low-density lipoprotein cholesterol(LDL-C),high-density lipoprotein cholesterol(HDL-C)were compared between the two groups,the levels of hypersensitive C reactive protein(hs-CRP)before and after treatment were measured and compared between the two groups,the adverse reactions of patients during medication were observed.Results The TC、TG、LDL-C control compliance rates in the combined treatment group were higher than those in the atorvastatin group(P<0.05).There was no significant difference in HDL-C control compliance rate between the two groups(P>0.05).After treatment,the hs-CRP of both groups was lower than that before treatment,and the hs-CRP of the combined treatment group was lower than that of Atorvastatin group(P<0.05).The total adverse reaction rate in the combined treatment group was 5.77%,which was lower than 19.61%in the Atorvastatin group(P<0.05).Conclusion Patients with coronary heart disease and hyperlipidemia treated with Lipopitride combined with Atorvastatin can play a better lipid-lowering effect,improve their blood lipid indicators,and reduce hs-CRP levels.

关 键 词：脂必泰 阿托伐他汀 联合治疗 冠心病 高脂血症 超敏C反应蛋白 

分 类 号：R589.2[医药卫生—内分泌]